252 related articles for article (PubMed ID: 8012971)
41. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.
Friedman HS; Colvin OM; Skapek SX; Ludeman SM; Elion GB; Schold SC; Jacobsen PF; Muhlbaier LH; Bigner DD
Cancer Res; 1988 Aug; 48(15):4189-95. PubMed ID: 3390813
[TBL] [Abstract][Full Text] [Related]
42. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE
Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853
[TBL] [Abstract][Full Text] [Related]
43. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).
Mattern MR; Hofmann GA; McCabe FL; Johnson RK
Cancer Res; 1991 Nov; 51(21):5813-6. PubMed ID: 1657371
[TBL] [Abstract][Full Text] [Related]
44. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
Emmons M; Boulware D; Sullivan DM; Hazlehurst LA
Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798
[TBL] [Abstract][Full Text] [Related]
45. Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR).
Dong Q; Johnson SP; Colvin OM; Bullock N; Kilborn C; Runyon G; Sullivan DM; Easton J; Bigner DD; Nahta R; Marks J; Modrich P; Friedman HS
Cancer Chemother Pharmacol; 1999; 43(1):73-9. PubMed ID: 9923544
[TBL] [Abstract][Full Text] [Related]
46. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
48. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
[TBL] [Abstract][Full Text] [Related]
49. The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
Goldenberg GJ
Cancer Res; 1975 Jul; 35(7):1687-92. PubMed ID: 1055634
[TBL] [Abstract][Full Text] [Related]
50. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.
Mitchell RB; Moschel RC; Dolan ME
Cancer Res; 1992 Mar; 52(5):1171-5. PubMed ID: 1737376
[TBL] [Abstract][Full Text] [Related]
51. Tumour levels of O6-alkylguanine-DNA-alkyltransferase and sensitivity to BCNU of human xenografts.
Tagliabue G; Citti L; Massazza G; Damia G; Giavazzi R; D'Incalci M
Anticancer Res; 1992; 12(6B):2123-5. PubMed ID: 1295458
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.
Bacolod MD; Johnson SP; Ali-Osman F; Modrich P; Bullock NS; Colvin OM; Bigner DD; Friedman HS
Mol Cancer Ther; 2002 Jul; 1(9):727-36. PubMed ID: 12479369
[TBL] [Abstract][Full Text] [Related]
53. Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatments with melphalan in vitro.
Barranco SC; Townsend CM; Weintraub B; Beasley EG; MacLean KK; Shaeffer J; Liu NH; Schellenberg K
Cancer Res; 1990 Jun; 50(12):3614-8. PubMed ID: 2340510
[TBL] [Abstract][Full Text] [Related]
54. Potentiation of BCNU anticancer activity by O6-benzylguanine: a study in vitro and in vivo.
Wan Y; Wu D; Gao H; Lu H
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):69-75. PubMed ID: 10905510
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of cross-resistance between radiation and antineoplastic drugs.
Ozols RF; Masuda H; Hamilton TC
NCI Monogr; 1988; (6):159-65. PubMed ID: 3352759
[TBL] [Abstract][Full Text] [Related]
56. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Kurpad SN; Dolan ME; McLendon RE; Archer GE; Moschel RC; Pegg AE; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1997; 39(4):307-16. PubMed ID: 9025771
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
58. Development and characterization of a melphalan-resistant human multiple myeloma cell line.
Bellamy WT; Dalton WS; Gleason MC; Grogan TM; Trent JM
Cancer Res; 1991 Feb; 51(3):995-1002. PubMed ID: 1988143
[TBL] [Abstract][Full Text] [Related]
59. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
60. O6-benzylguanine-mediated enhancement of chemotherapy.
Friedman HS; Keir S; Pegg AE; Houghton PJ; Colvin OM; Moschel RC; Bigner DD; Dolan ME
Mol Cancer Ther; 2002 Sep; 1(11):943-8. PubMed ID: 12481416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
